WP03 - Quality Control
The goal is to facilitate the use of human brain tissue in research and to supply researchers in various fields of neuroscience with brain tissue of optimal quality (see also WP01). This requires security of both clinical and neuropathological diagnoses (see also WP15). Security in neuropathological diagnostics is based on sections stained in an optimal way. The techniques used in diagnostics include not only conventional staining techniques but also immunohistochemistry and in situ hybridisation both being methods carried out in a variable way. Furthermore issues related to sampling strategies (WP01) are known to influence the staining results. This  work package deals with issues related to standardisation of staining methodologies to be used in neuropathological diagnostics and research.

One further task of this WP is to list detailed instructions to be used for separate staining techniques on the BrainNet Europe website. Special emphasis is on immunohistochemical stainings for which detailed instructions regarding post-mortem delay, fixation time, recommended antibodies to be used and pre-treatments are to be given. As an example for diagnostics of Alzheimer's disease ß-amyloid antibody staining is needed. The staining results are not influenced significantly by the post-mortem delay, fixation or paraffin embedding. Pre-treatment with formic acid is obligatory. This information is followed by a detailed step to step instruction how to proceed in order to obtain optimal results. Similar instructions are to be given for various antibodies.

Workpackage Leader


Prof. Dr. Irina Alafuzoff MD PhD

Phone: +358 (17) 162877 
Fax: +358 (17) 162048 
Prof. Dr. Irina Alafuzoff MD PhD


previous / next

back next
 



Copyright (c) BrainNet Europe, coordinated by the Centre for Neuropathology and Prion Research, Ludwig- Maximilians-University Munich, Germany. Tel.: +49-89-2180-78001

Video BrainNet Europe


Click to watch the video.

Consortium Participants

 

Workpackage Structure